Natural Capsules Limited

Annual Quarterly₹ CrorePeersNECLIFE AAREYDRUGS BALPHARMA ALPA KREBSBIO MEDICAMEQ MEDICO VINEETLAB

View

In ₹ Crore except Per Share 12 Months Ending	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	45.0	45.2	45.8	37.7	58.5	48.7
Other Income	0.3	0.4	0.2	0.4	0.8	2.4
Total Income	45.3	45.6	46.0	38.2	59.2	51.1
Expenses
+ Cost of Materials Consumed	22.9	23.6	24.8	25.3	29.5	28.9
+ Changes in Inventories	-0.1	-0.0	-0.5	-6.4	6.0	-3.0
+ Employee Benefit Expense	3.7	5.4	5.5	5.7	5.5	5.2
+ Finance Costs	1.6	2.5	2.7	2.8	2.9	5.0
+ Depreciation & Amortisation	2.2	4.2	4.3	4.4	4.3	4.3
+ Other Expenses	14.1	15.9	16.8	15.4	16.2	16.4
Total Expenses	44.4	51.6	53.7	47.3	64.3	56.9
EBITDA	4.4	0.3	-0.9	-2.3	1.3	1.1
EBIT	2.2	-3.9	-5.2	-6.7	-3.0	-3.2
Profit
PBT before Exceptional Items	0.9	-6.1	-7.7	-9.1	-5.1	-5.8
Pretax Income	0.9	-6.1	-7.7	-9.1	-5.1	-5.8
+ Current Tax	-0.3	0.9	0.9	0.0	1.9	1.5
+ Deferred Tax	0.6	-1.4	-1.6	-2.0	-2.0	-1.6
Tax Expense	0.4	-0.5	-0.7	-2.0	-0.1	-0.1
Net Income	0.5	-5.6	-7.0	-7.1	-5.0	-5.7
+ Net Income — Continuing Ops	0.5	-5.6	-7.0	-7.1	-5.0	-5.7
+ Other Comprehensive Income	-0.4	0.0	0.0	0.0	-0.0	0.0
Total Comprehensive Income	0.1	-5.6	-7.0	-7.1	-5.0	-5.7
Net Income to Common	—	—	—	0.0	-3.4	-4.0
Minority Interest	—	—	—	0.0	-1.5	-1.8
Per Share
Basic EPS	0.13	-5.40	-6.76	-6.88	-4.82	-5.55
Diluted EPS	0.13	-5.40	-6.76	-6.85	-4.80	-5.54
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.4	—	—	—	-0.0	0.0
+ Items NOT to be Reclassified to P&L	—	—	—	—	-0.0	—
+ Tax on Items NOT to be Reclassified	0.4	—	—	—	0.0	0.0
Comprehensive Income — Owners of Parent	—	—	—	0.0	-3.4	-4.0
Comprehensive Income — Non-controlling Interests	—	—	—	0.0	-1.5	-1.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.13	-5.40	-6.76	-6.88	-4.82	-5.55
Diluted EPS — Continuing Operations	0.13	-5.40	-6.76	-6.85	-4.80	-5.54
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	22.2	21.6	21.5	18.8	23.0	22.8
Gross Margin %	49.29	47.85	46.91	49.74	39.30	46.72
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	0.9	-6.1	-7.7	-9.1	-5.1	-5.8
Net Income Adj (tax-effected)	0.5	-5.6	-7.0	-7.1	-5.0	-5.7
EPS Adj	0.13	-5.40	-6.76	-6.88	-4.82	-5.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	0.40	0.00	—	—	—	—
Paid Up Equity Capital	10.3	10.3	10.3	10.3	10.4	10.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.